Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

Howard Gurney, Edson Sydney de Campos*, David Dodwell, Arvind Kamthan, Nicholas Thatcher

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

Original languageEnglish
Pages (from-to)565-567
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number5
DOIs
Publication statusPublished - 1991
Externally publishedYes

Fingerprint Dive into the research topics of 'Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this